Drug intelligence / Profile preview

alprazolam + granisetron

Development stage
Preclinical
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Intravenous, Transdermal
01

Overview

This is a combination of two small molecule drugs, alprazolam and granisetron. Alprazolam is a triazolobenzodiazepine used primarily for the treatment of anxiety and panic disorders; it acts as a positive allosteric modulator at the GABA~A~ receptor, enhancing inhibitory neurotransmission in the central nervous system[3][5]. Granisetron is a selective serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting associated with cancer chemotherapy, radiation therapy, or surgery by blocking serotonin-mediated emetic signals in both the gut and brain[1][6][8][10]. The combination has been studied for enhanced control of chemotherapy-induced nausea and vomiting (CINV), particularly in patients receiving moderately or highly emetogenic regimens. Clinical studies indicate that adding alprazolam to granisetron may improve antiemetic efficacy compared to granisetron alone, especially during acute phases post-chemotherapy[2][7].

Other names
alprazolam and granisetronalprazolam plus granisetron
02

Targets

GABRR (GABA-A receptor subunit rho)HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on alprazolam + granisetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alprazolam + granisetron.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call